Imagine a small sticker that uses gentle sound waves to temporarily open tiny doors in your skin. This allows large medicines, which usually require a needle, to slide right in without any pain. Once the device is turned off, the doors close back up, keeping everything safe and secure.
Chronic patients suffer from low treatment adherence (only 1 in 3 reach goals) because needles and cannulas cause pain, infection risks, and social rejection.
A 4x2x1cm wearable device using sonophoresis to open skin pores for needle-free drug delivery, featuring a 3-year durable component and a 2mL disposable reservoir.
If you are a biotech company dealing with low patient adherence to injectable macromolecules like insulin or heparin — this project developed a wearable smartpatch that delivers drugs up to 200KDa without needles. This removes the pain and frustration that causes 38% of chronic patients to discontinue treatment.
If you are a device manufacturer dealing with the limitations of subcutaneous cannulas — this project developed a 4x2x1cm device that uses sonophoresis to reach the hypodermis. It offers a durable part with a 3-year warranty and a recyclable disposable reservoir.
If you are an insurance provider dealing with the 20% higher care costs associated with poorly controlled chronic patients — this project developed a painless delivery system to improve treatment goals. Increasing the 35% achievement rate for treatment goals reduces hospitalizations and long-term care costs.
Based on available project data, specific pricing is not mentioned, but the system consists of a durable part with a 3-year warranty and a disposable, recyclable piece for the drug reservoir.
The project focuses on full commercialization of the Smartpatch, indicating it is moving toward industrial scale, though specific manufacturing volumes are not listed.
The solution is based on a patented electronic system, though specific licensing terms are not provided in the project summary.
It is designed for macromolecules up to 200KDa, specifically mentioning insulin, heparin, and EPO (>50KDa), without altering the drug's pharmacokinetic profile.
The project period runs from 2023-08-01 to 2026-05-31, focusing on full commercialization during this window.
The project is led by a single Spanish SME, Medicsensors SL, with a 100% industry ratio. This lean structure suggests a fast-track commercialization path typical of EIC Accelerator projects, focusing on direct market entry rather than academic research.
Contact Medicsensors SL in Spain regarding the Smartpatch commercialization
Contact us to explore licensing or partnership opportunities with Medicsensors SL.
